FibroBiologics, Inc.
FBLGNasdaq
$0.83
↓ -0.6%Jul 17 close · end-of-day
Price
1Y↓ -94.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$3.2M
Enterprise Value
$1.7M
P/E
0.9
P/S
—
P/B
1.2
EV/EBITDA
—
PEG
—
FCF Yield
-498.5%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$18.7M
Free Cash Flow (TTM)
-$15.7M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-718.5%
ROIC
-1214.4%
Debt / Equity
—
Net Cash
$1.5M
Return 1Y
-94.0%
Company profile
We are a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and for potential extension of life applications including thymic and splenic involution reversal. We were formed in April 2021 as a Texas limited liability company under the name FibroBiologics, LLC, and converted to a Delaware corporation in December 2021 under the name Fibrobiologics, Inc. On April 12, 2023, we changed our name to FibroBiologics, Inc. Our principal executive offices are located at 455 E. Medical Center Blvd., Suite 300, Houston, Texas.
- CEO
- Pete O’Heeron
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- Texas
- Website
- fibrobiologics.com
Management & directors
- Khoja HamidChief Scientific Officer
- O'Heeron PeteCHIEF EXECUTIVE OFFICER
- Davis JasonChief Financial Officer
- Garcia Ruben AGeneral Counsel
Roles derived from SEC Form 4 filings.
Earnings
FBLG Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$1.33↓ -50.9%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$4.5M | -$8.9M | -$13.7M | -$16.6M |
| Net income | -$5.1M | -$16.5M | -$11.2M | -$18.6M |
| Diluted EPS | -$0.18 | -$0.68 | -$0.34 | -$0.42 |
| Operating cash flow | -$4.1M | -$6.4M | -$11.9M | -$16.4M |
| Free cash flow | — | -$6.9M | -$12.1M | -$16.7M |
| Gross margin | — | — | — | — |
| Operating margin | — | — | — | — |
| Net margin | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$3.2M | -$3.4M | -$3.7M | -$4.5M | -$4.5M | -$5.0M | -$2.6M | -$5.1M |
| Net income | $898,000.00 | -$500,000.00 | -$3.1M | -$5.0M | -$4.7M | -$5.8M | -$3.2M | -$5.0M |
| Diluted EPS | $0.03 | -$0.01 | -$0.09 | -$2.71 | -$0.12 | -$0.13 | $2.54 | -$1.33 |
| Operating cash flow | -$1.9M | -$2.6M | -$3.1M | -$5.3M | -$4.0M | -$4.0M | -$3.2M | -$4.4M |
| Free cash flow | -$2.0M | -$2.6M | -$3.2M | -$5.3M | -$4.2M | -$4.0M | -$3.2M | -$4.4M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 9, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-03-04 | Khoja Hamid· Chief Scientific Officer | Buy | 30,000 | $0.38 | $11,400.00 | filing |
| 2026-03-04 | O'HEERON PETE· CHIEF EXECUTIVE OFFICER | Buy | 15,872 | $0.38 | $6,005.96 | filing |
| 2026-03-03 | O'HEERON PETE· CHIEF EXECUTIVE OFFICER | Buy | 18,200 | $0.41 | $7,372.82 | filing |
| 2026-03-02 | Davis Jason· Chief Financial Officer | Buy | 70,000 | $0.41 | $28,973.00 | filing |
| 2026-03-02 | O'HEERON PETE· CHIEF EXECUTIVE OFFICER | Buy | 17,428 | $0.35 | $6,152.08 | filing |
| 2026-02-27 | GARCIA RUBEN A· General Counsel | Buy | 40,000 | $0.33 | $13,056.00 | filing |
| 2025-12-11 | GARCIA RUBEN A· General Counsel | Buy | 140,000 | $0.34 | $47,600.00 | filing |
Latest 7 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.